IP Library Granted Patent US 9,145,593
Granted Patent B2
US 9,145,593 · App. 13/461,122 · Granted Sep 29, 2015

Oligonucleotides useful in methods for detecting and characterizing

Inventors: Jason Trama (Burlington, NJ); Martin E Adelson (East Windsor, NJ); Eli Mordechai (Robbinsville, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
C12Q1/6895C12Q1/689C12Q2561/113C12Q2565/301C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,593
App. No.
13/461,122
Granted
Sep 29, 2015
Kind
B2
Abstract

Methods for using oligonucleotides in the detection of Aspergillus fumigatus are disclosed. The oligonucleotides of the invention have nucleotide sequences derived from the gene encoding the cytochrome P450 14 alpha-sterol demethylase (the cyp51A protein) of Aspergillus fumigatus . The oligonucleotides include primers capable of producing amplicons specific to cyp51A in polymerase chain reactions using nucleic acids isolated from Aspergillus fumigatus as templates. The oligonucleotides also include probes capable of detecting these cyp51A-specific amplicons. The oligonucleotides of the invention also include primers for nucleotide sequencing reactions to determine whether an isolate of Aspergillus fumigatus is more tolerant than wild-type Aspergillus fumigatus to a triazole.

Claims (9)

1. A method for determining the presence of Aspergillus fumigatus in whole blood of a human and whether said Aspergillus fumigatus is more tolerant to triazole than wild-type Aspergillus fumigatus , comprising the steps of:

(a) obtaining whole blood from a human subject, wherein said human subject is suspected of infection with triazole-resistant Aspergillus fumigatus;

(b) extracting DNA from said whole blood;

(c) performing a real-time PCR on said extracted DNA using a forward primer consisting of the nucleotide sequence SEQ ID NO: 16, a reverse primer consisting of the nucleotide sequence SEQ ID NO: 17 and a probe consisting of the nucleotide sequence SEQ ID NO: 26 to generate an amplicon, wherein the generation of said amplicon in said real-time PCR is indicative of the presence of Aspergillus fumigatus;

(d) isolating said generated amplicon;

(e) performing a pyrosequencing reaction on said isolated amplicon using a sequencing primer consisting of the nucleotide sequence SEQ ID NO: 18; and

(f) determining the identity of the nucleotides encoding the amino acid at position 54 of the Cyp51A protein, wherein the presence of an amino acid other than glycine at said position 54 is indicative of the presence of said Aspergillus fumigatus that is more tolerant to triazole than wild-type Aspergillus fumigatus.

2. The method of claim 1 , wherein said probe is dual-florescence labeled to detect said generated amplicon.

3. The method of claim 1 , wherein said reverse primer is biotinylated at its 5′ end to facilitate said isolation of said generated amplicon.

Assignments (4)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (3)
Division 11299362 · Dec 9, 2005
Provisional Application 60636133 · Dec 15, 2004
Related Publication 20130230848A1 · Sep 5, 2013